Improved exercise tolerance after losartan and enalapril in heart failure: Correlation with changes in skeletal muscle myosin heavy chain composition

Circulation

Volumn 98, Issue 17, 1998, Pages 1742-1749

  Vescovo, Giorgio ^a   Dalla Libera, Luciano ^b   Serafini, Francesco ^a   Leprotti, Cristiana ^a   Facchin, Luigi ^a   Volterrani, Maurizio ^c   Ceconi, Claudio ^c   Ambrosio, Giovanni Battista ^a  

^a Venice City Hospital   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c IRCCS   (Italy)

Author keywords

Exercise; Heart failure; Muscles; Myosin

Indexed keywords

ENALAPRIL; LOSARTAN; MYOSIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE TOLERANCE; GASTROCNEMIUS MUSCLE; HUMAN; HUMAN TISSUE; LUNG VENTILATION; MALE; MUSCLE FATIGUE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; SKELETAL MUSCLE;

EID: 0345019803     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.17.1742     Document Type: Article

References (52)

1. Minotti JR, Pillay P, Chang L, Wells L, Massie BM. Neurophysiological assessment of skeletal muscle fatigue in patients with congestive heart failure. Circulation. 1992;86:903-908.
2. Harridge SPR, Magnusson G, Gordon A. Skeletal muscle contractile characteristics and fatigue resistance in patients with chronic heart failure. Eur Heart J. 1996;17:896-901.
3. Wiener DH, Fink LI, Maris J, Jones RA, Chance B, Wilson JR. Abnormal skeletal muscle bioenergetics during exercise in patients with heart failure: role of reduced muscle blood flow. Circulation. 1986;73: 1127-1136.
4. 31P nuclear magnetic resonance spectroscopy study of leg muscle. Clin Sci. 1990;79:583-589.
5. Mancini DM, Ferraro N, Tuchler M, Chance B, Wilson JR. Detection of abnormal calf muscle metabolism in patients with heart failure using phosphorus-31 nuclear magnetic resonance. Am J Cardiol. 1988;62: 1234-1240.
6. Massie BM, Conway M, Rajagopalan B. Skeletal muscle metabolism during exercise under ischemic conditions in congestive heart failure: evidence for abnormalities unrelated to blood flow. Circulation. 1988; 78:320-326.
7. 31P nuclear magnetic resonance evidence of abnormal skeletal muscle metabolism in patients with congestive heart failure. Am J Cardiol. 1987;60:309-315.
8. Wilson JR, Fink LI, Maris J, Ferraro N, Power-Vanwart J, Eleff S, Chance B. Evaluation of energy metabolism in skeletal muscle of patients with heart failure with gated phosphorus-31 nuclear magnetic resonance. Circulation. 1985;71:57-62.
9. Lipkin DP, Jones DA, Round JM, Poole-Wilson PA. Abnormalities of skeletal muscle in patients with chronic heart failure, Int J Cardiol. 1988;18:187-195.
10. Sullivan MJ, Green HJ, Cobb FR. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation. 1990;81:518-527.
11. Vescovo G, Serafini F, Facchin L, Tenderini L, Carraro U, Dalla Libera L, Catani C, Ambrosio GB. Specific changes in skeletal muscle myosin heavy chain composition in cardiac failure: differences with disuse atrophy as assessed on microbiopsies by a new electrophoretic micro-method. Heart. 1996;76:337-343.
12. Vescovo G, Serafini F, Dalla Libera L, Leprotti C, Facchin L, Tenderini P, Ambrosio GB. Skeletal muscle myosin heavy chain composition in CHF: correlation between the magnitude of the isoenzymatic shift, exercise capacity, and gas exchange measurements. Am. Heart J. 1998; 135:130-137.
13. Garg R, Yusuf S. Overview of randomized trials of Angiotensin-converting enzyme on mortality and morbidity in patients with congestive heart failure. Collaborative Group on ACE Inhibitor Trials [published erratum appears in JAMA. 1995;274:462]. JAMA. 1995;273:1450-1458.
14. Linz W, Scholkens BA. A specific B-2 bradykinin receptor antagonist HOE 140 abolishes the anti-hypertrophic effect of ramipril. Br J Pharmacol. 1992;104:771-779.
15. Minotti JR, Johnson EC, Hudson TL, Zuroske G, Fukushima E, Murata G, Wise LE, Chick TW, Icenogle MV. Training-induced skeletal muscle adaptations are independent of systemic adaptations. J Appl Physiol. 1990;68:289-294.
16. Minotti JR, Johnson EC, Hudson TL, Zuroske G, Murato G, Fukushima E, Cagle TG, Chick TW, Massie BM, Icenagle MV. Skeletal muscle response to exercise training in congestive heart failure. J Clin Invest. 1990;86:751-758.
17. Coats AJS, Adamopoulos S, Radaelli A, McCance A, Meyer TE, Bernardi L, Solda PL, Davey P, Ormerord O, Forfar C, Conway J, Sleight P. Controlled trial of physical training in chronic heart failure. Circulation. 1992;85:2119-2131.
18. Belardinelli R, Georgiou D, Scocco V, Barstow TJ. Purcaro A. Low intensity exercise training in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:975-982.
19. Gollnick PD, Saltin B. Significance of skeletal muscle oxidative enzyme enhancement with endurance training. Clin Physiol. 1982;2:1-12.
20. Holloszy JO, Booth FW. Biochemical adaptations to endurance exercise in muscle. Annu Rev Physiol. 1976;38:273-291.
21. Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with chronic heart failure delays ventilatory anaerobic threshold and improves submaximal exercise performance. Circulation. 1989;79: 324-329.
22. Hambrecht R, Fiehn E, Yu J, Niebauer J, Weigl C, Hilbrich L, Adams V, Riede U, Schuler G. Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart. J Am Coll Cardiol. 1997;29:1067-1073.
23. Schaufelberger M, Andersson G, Eriksson BO, Grimby G, Held P, Swedberg K. Skeletal muscle changes in patients with chronic heart failure before and after treatment with enalapril. Eur Heart J. 1996;17: 1678-1685.
24. Munzel T, Kurz S, Drexler H. Are alterations of skeletal muscle ultrastructure in patients with heart failure reversible under treatment with ACE inhibitors? Herz. 1993;18(suppl 1):400-405.
25. Gottleib SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKeck M. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;88:1602-1609.
26. Pitt B, Segal R, Martinez FA, Murers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet. 1997;349:747-752.
27. Harding SE, Jones SM, O'Gara P, Dal Monte F, Vescovo G, Poole-Wilson PA. Isolated ventricular myocytes from failing and non-failing human hearts: the relation of age and clinical status of patients to isoproterenol response. J Mol Cell Cardiol. 1992;24:549-564.
28. Wasserman K. The anaerobic threshold measurement to evaluate exercise performance. Am Rev Respir Dis. 1984;129(suppl):S35-S40.
29. Carraro U, Catani C. A sensitive SDS-PAGE method for separating MHC isoforms of rat skeletal muscles reveals the heterogeneous nature of the embryonic myosins. Biochem Biophys Res Commun. 1983;116:793-802.
30. Vescovo G, Ceconi C, Bernocchi P, Ferrari R, Carraro U, Ambrosio GB, Dalla Libera L. Skeletal muscle myosin heavy chain expression in rats with monocrotaline-induced cardiac hypertrophy and failure: relation to blood flow and degree of muscle atrophy. Cardiovasc Res. In press.
31. Jondeau G, Katz SD, Toussaint JF, Dubourg O, Monrad ES. Regional specificity of peak hyperemic response in patients with congestive heart failure: correlation with peak aerobic capacity. J Am Coll Cardiol. 1993; 22:1399-1402.
32. Guazzi M, Agostoni PG, Marenzi GC, Melzi G, Guazzi MD. Similar efficacy (but different mechanisms) on exercise capacity of losartan (LOS) and enalapril (EN) in chronic heart failure (CHF). J Am Coll Cardiol. 1997;29(2A):205. Abstract.
33. Mancini DM, Coyle E, Coggan A. Contribution of intrinsic skeletal muscle changes to 31P NMR skeletal muscle metabolic abnormalities in patients with chronic heart failure. Circulation. 1989;80:1338-1346.
34. Massie BM, Conway M, Yonge R. Skeletal muscle metabolism in patients with congestive heart failure: relation to clinical severity and blood now. Circulation. 1987;76:1009-1019.
35. Minotti JR, Christoph I, Oka R, Weiner MW, Wells L, Massie BM. Impaired skeletal muscle function in patients with congestive heart failure: relationship to systemic exercise performance. J Clin Invest. 1991;88:2077-2082.
36. Drexler H, Riede U, Munzel T, Konig H, Funke E, Jiust H. Alterations of skeletal muscle in chronic heart failure. Circulation. 1992;85:1751-1759.
37. Wilson JR, Martin JL, Schwartz D, Ferraro N. Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle. Circulation. 1984;69:1079-1087.
38. Massie BM, Simonini A, Sahgal P, Wells L, Dudley GA. Relation of systemic and local muscle exercise capacity to skeletal muscle characteristics in men with congestive heart failure. J Am Coll Cardiol. 1996; 27:140-145.
39. Belardinelli R, Scocco V, Purcaro A. Low intensity exercise training improves skeletal muscle oxidative capacity without changes in capillary growth in chronic heart failure. Circulation. 1995;92:I-399. Abstract.
40. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, Kjekshus J. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 26:438-445.
41. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumor necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J. 1994;15:1528-1532.
42. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor independent mechanism. J Clin Invest. 1996;97:2509-2516.
43. Anker SD, Swan JW, Volterrani M, Chua TP, Clark AL, Poole-Wilson PA, Coats AJS. The influence of muscle mass, strength, fatigability, and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J. 1996;18:259-269.
44. Sullivan MJ, Knight JD, Higginbotham MB, Cobb FR. Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Circulation. 1989;80:769-780.
45. Fink LI, Wilson J R, Ferraro N. Exercise ventilation and pulmonary artery wedge pressure in chronic stable heart failure. Am J Cardiol. 1986;57: 249-253.
46. Minotti JR, Oka RK, Wells LM, Christoph I, Massie BM. Significance of muscle atrophy in heart failure. Circulation. 1991;84(suppl II):II-50. Abstract.
47. Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, Wilson JR. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation. 1992; 85:1364-1373.
48. Minotti JR, Pillay P, Oka R, Wells L, Christoph I, Massie BM. Skeletal muscle size: relationship to muscle function in heart failure. J Appl Physiol. 1993;75(1):373-381.
49. Simonini A, Lang CS, Dudley GA, Yue P, McElhinny J, Marrie BM. Heart failure in rats causes changes in skeletal muscle morphology and gene expression that are not explained by reduced activity. Circ Res. 1996;79:128-136.
50. Ruegg JC. Calcium in Muscle Contraction: Cellular & Molecular Physiology. 2nd ed. New York, NY: Springer Verlag, 1992:125.
51. Chapmans SJ, Grindrod SR, Jones DA. Cross-sectional area and force production of the quadriceps muscle. J Physiol. 1984;353-53P. Abstract.
52. Sullivan MJ, Higginbotham MB, Cobb FR. Increased exercise ventilation in patients with chronic heart failure: intact ventilatory control despite hemodynamic and pulmonary abnormalities. Circulation. 1988;77: 552-559.